Novel Therapeutic Strategies for Atopic Dermatitis: Biomarker Modulation and Clinical Implications. A Systematic Review

Novel Therapeutic Strategies for Atopic Dermatitis: Biomarker Modulation and Clinical Implications. A Systematic Review

Atopic dermatitis (AD), commonly known as eczema, is one of the most prevalent chronic inflammatory skin conditions worldwide. It is characterised by dry skin, persistent itching and recurrent eczematous lesions. The condition affects approximately 20% of children and 10% of adults, with its prevalence varying across populations and geographical regions.

Atopic dermatitis is a complex, multifactorial disease involving genetic susceptibility, impaired skin barrier function, alterations in the skin microbiome and immune system dysregulation. Advances in understanding these underlying mechanisms have contributed to the development of innovative systemic therapies targeting specific inflammatory pathways.

A systematic review published in Clinical Reviews in Allergy & Immunology examines how biologic therapies, Janus kinase (JAK) inhibitors and emerging treatments influence biomarkers associated with atopic dermatitis, and how these changes relate to clinical outcomes.

1. Understanding the Inflammatory Mechanisms of Atopic Dermatitis

The development of atopic dermatitis involves an interaction between skin barrier dysfunction and abnormal immune responses.

Mutations in the filaggrin gene (FLG), which encodes an important structural protein of the skin barrier, can contribute to impaired barrier function. This increases transepidermal water loss and promotes skin dryness, while also facilitating the penetration of allergens and irritants.

These changes trigger inflammatory responses involving several immune cells and cytokines. Among these, the T-helper 2 (Th2) pathway plays a central role in atopic dermatitis.

Key cytokines involved include:

  • IL-4 and IL-13: Important mediators of Th2-driven inflammation.
  • IL-31: Associated with itching and inflammatory responses.
  • IL-5: Involved in eosinophilic inflammation.

Understanding these pathways has enabled the development of targeted therapies that interfere with specific components of the inflammatory response.

2. Biologic Therapies: Targeting Key Immune Pathways

Biologic therapies work by selectively targeting cytokines or their receptors involved in atopic dermatitis.

The review identifies several biologic agents that have been investigated for their effects on disease-related biomarkers.

Dupilumab

Dupilumab targets the alpha subunit of the IL-4 receptor (IL-4Rα), inhibiting both IL-4 and IL-13 signalling. It was the most extensively investigated biologic in the studies included in the review.

Research demonstrated reductions in several inflammatory biomarkers, including CCL17, lactate dehydrogenase (LDH) and total immunoglobulin E (IgE).

Tralokinumab

Tralokinumab selectively targets IL-13, an important cytokine involved in Th2-mediated inflammation. Studies reported reductions in several inflammatory markers and changes in cytokine profiles associated with clinical improvement.

Nemolizumab

Nemolizumab targets the IL-31 receptor, addressing a pathway associated with itching in atopic dermatitis. The review included a study investigating its effects on disease-related biomarkers.

These findings demonstrate how biologic therapies can influence inflammatory activity beyond their effects on visible skin symptoms.

3. JAK Inhibitors: Modulating Inflammatory Signalling

Janus kinase inhibitors represent another important therapeutic approach discussed in the review.

The JAK-STAT signalling pathway is involved in transmitting signals from several cytokines that contribute to inflammation. By inhibiting this pathway, JAK inhibitors can influence multiple immune responses.

The review examined three JAK inhibitors:

  • Upadacitinib: A selective JAK1 inhibitor investigated for its effects on inflammatory biomarkers and clinical outcomes.
  • Abrocitinib: Another selective JAK1 inhibitor associated with changes in inflammatory gene expression and disease severity.
  • Baricitinib: A JAK1/JAK2 inhibitor evaluated for its influence on biomarkers associated with atopic dermatitis.

Unlike biologic agents that target specific cytokines or receptors, JAK inhibitors influence intracellular signalling pathways involving multiple cytokines.

However, the review found that biomarker changes with JAK inhibitors were not always consistent across studies, reflecting their broader immunomodulatory effects.

4. Emerging Therapies: Exploring New Therapeutic Targets

Beyond established biologics and JAK inhibitors, the review examines emerging therapies that target different stages of immune activation.

These include:

OX40/OX40L inhibitors

The OX40-OX40L pathway is involved in T-cell activation and immune regulation. Agents such as amlitelimab and GBR830 have been investigated for their potential to modulate inflammatory responses.

JAK/SYK inhibitors

ASN002, an oral dual JAK/SYK inhibitor, has been studied for its effects on inflammatory pathways involved in atopic dermatitis.

TSLP inhibitors

Tezepelumab targets thymic stromal lymphopoietin (TSLP), an epithelial cytokine involved in initiating and amplifying inflammatory responses.

IL-4Rα inhibitors

Emerging agents, including rademikibart, AKN120 and stapokibart, have also been investigated for their ability to influence IL-4 and IL-13 signalling.

The review highlights that evidence for these emerging therapies remains limited, with available studies primarily involving early-phase clinical trials.

5. Biomarkers: Understanding Disease Activity and Treatment Response

One of the central themes of the systematic review is the role of biomarkers in evaluating disease activity and monitoring therapeutic responses.

Biomarkers are measurable biological indicators that can provide insights into inflammatory activity and changes following treatment.

The review identifies several biomarkers that have been investigated in patients receiving systemic therapies for atopic dermatitis.

CCL17/TARC

CCL17, also known as thymus and activation-regulated chemokine (TARC), is one of the most extensively studied biomarkers in atopic dermatitis.

The review found that CCL17 levels decreased consistently following treatment across different therapeutic classes. These reductions were also associated with improvements in clinical severity scores, including Eczema Area and Severity Index (EASI) and SCORing Atopic Dermatitis (SCORAD).

Lactate Dehydrogenase (LDH)

LDH is another frequently investigated biomarker. Studies included in the review reported reductions in LDH levels following treatment.

In patients receiving dupilumab, reductions in LDH were associated with improvements in EASI scores. Higher baseline LDH levels were also associated with potentially poorer treatment responses in some studies.

Immunoglobulin E (IgE)

IgE is an important component of allergic immune responses and has been investigated as a potential marker of disease activity.

Most studies examining dupilumab reported reductions in total IgE levels following treatment. Reductions were also observed in studies involving tralokinumab, upadacitinib and certain emerging therapies.

Eosinophils

Eosinophil counts demonstrated variable responses across treatment studies. While counts remained stable or increased in several dupilumab studies, upadacitinib generally showed reductions.

These findings suggest that different therapies may influence inflammatory markers in distinct ways.

6. Molecular Profiling: Understanding Changes Beyond Conventional Biomarkers

The review also highlights the growing importance of molecular profiling techniques in understanding treatment responses.

Transcriptomics, proteomics, metabolomics and lipidomics allow researchers to investigate changes in gene expression, proteins, metabolites and lipids associated with atopic dermatitis.

Studies examining dupilumab and tralokinumab demonstrated reductions in genes associated with inflammatory pathways, alongside increased expression of genes involved in skin barrier function and lipid metabolism.

Abrocitinib was also associated with reduced expression of genes involved in inflammation, epidermal hyperplasia and Th2/Th22 responses.

Proteomic studies identified reductions in several immune mediators, including CCL13, CCL17 and S100 proteins, following treatment with biologic therapies.

Metabolomic and lipidomic investigations in dupilumab-treated patients also identified changes in fatty acid profiles among treatment responders.

These findings provide additional insights into the molecular changes associated with therapeutic responses.

7. Skin Microbiome and Barrier Function: An Important Connection

Alterations in the skin microbiome and impaired barrier function are important features of atopic dermatitis.

The review highlights the relationship between systemic therapies, microbial balance and skin barrier recovery.

Studies investigating dupilumab consistently reported reductions in Staphylococcus aureus colonisation. Similar findings were reported in a study involving tralokinumab.

These changes were associated with improvements in clinical disease severity.

The review also discusses the role of skin barrier measurements, including transepidermal water loss (TEWL) and stratum corneum hydration (SCH).

One study found that changes in stratum corneum hydration after 16 weeks of dupilumab treatment could serve as early indicators of sustained treatment response.

Together, these findings suggest that improvements in immune regulation may be accompanied by changes in skin microbial balance and barrier function.

8. Moving Towards Personalised Treatment in Atopic Dermatitis

The findings of this systematic review highlight the potential of biomarkers and molecular profiling in improving the understanding of atopic dermatitis and its treatment responses.

CCL17 and LDH emerged as particularly consistent biomarkers associated with disease severity and therapeutic response. However, their limited specificity presents challenges for their use as independent clinical indicators.

The authors also highlight the importance of combining immunological, transcriptomic and microbiomic information to develop more comprehensive biomarker panels.

Such integrated approaches could contribute to identifying disease patterns, evaluating treatment responses and supporting future precision medicine strategies.

However, differences in study designs, patient populations, analytical techniques and biomarker measurements currently limit the comparability of findings. Further research is necessary to validate these biomarkers and establish their clinical applications.

Conclusion

Advances in biologic therapies, JAK inhibitors and emerging targeted treatments are providing new insights into the management of atopic dermatitis.

The findings of this systematic review demonstrate that therapeutic responses extend beyond improvements in clinical symptoms, involving changes in inflammatory biomarkers, immune signalling, gene expression, skin microbiome composition and barrier function.

Although several biomarkers have demonstrated promising associations with treatment outcomes, further validation is required before their widespread application in clinical practice.

Continued research into these interconnected mechanisms may help advance a more personalised approach to atopic dermatitis management.

Reference:

Moreiras-Arias N, Nieto-Fontarigo JJ, Salgado FJ, et al. (2026). Novel Therapeutic Strategies for Atopic Dermatitis: Biomarker Modulation and Clinical Implications. A Systematic Review. Clinical Reviews in Allergy & Immunology, 69, Article 4. https://doi.org/10.1007/s12016-025-09129-z